Case report: Non-response to fluoxetine in a homozygous 5-HTTLPR S-allele carrier of the serotonin transporter gene.
5-HTT
ABCB1
SLC6A4
depression
pharmaceutical care
pharmacodynamics
pharmacogenetics
venlafaxine
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
05
2022
accepted:
28
06
2022
entrez:
1
8
2022
pubmed:
2
8
2022
medline:
2
8
2022
Statut:
epublish
Résumé
We report the case of a 50-year-old male with major depressive disorder (MDD) to illustrate the challenge of finding effective antidepressant pharmacotherapy and the role that the patient's genetic makeup may play. Recent treatment attempts before clinic admission included venlafaxine and fluoxetine. Venlafaxine was discontinued due to lack of response, and subsequently switched to fluoxetine based on pharmacogenotyping of the P-glycoprotein transporter (P-gp, encoded by
Identifiants
pubmed: 35911243
doi: 10.3389/fpsyt.2022.942268
pmc: PMC9334565
doi:
Types de publication
Case Reports
Langues
eng
Pagination
942268Informations de copyright
Copyright © 2022 Stäuble, Meier, Lampert, Mikoteit, Hatzinger, Allemann, Hersberger and Meyer zu Schwabedissen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
CNS Spectr. 2014 Apr;19(2):165-75
pubmed: 23880209
Eur Neuropsychopharmacol. 2012 Apr;22(4):239-58
pubmed: 22137564
ACS Chem Neurosci. 2019 Jul 17;10(7):3120-3131
pubmed: 30589533
J Clin Psychiatry. 1999;60 Suppl 4:4-11; discussion 12-3
pubmed: 10086478
Neuropsychopharmacology. 2000 Apr;22(4):380-7
pubmed: 10700657
Science. 2003 Jul 18;301(5631):386-9
pubmed: 12869766
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62
pubmed: 28910830
Drug Metab Dispos. 2005 Jan;33(1):165-74
pubmed: 15502009
J Pers Med. 2021 Dec 09;11(12):
pubmed: 34945806
J Affect Disord. 2020 Aug 1;273:254-264
pubmed: 32421611
Pharmacogenomics. 2020 Nov;21(16):1145-1150
pubmed: 33124517
Eur J Clin Pharmacol. 2004 Feb;59(12):869-73
pubmed: 14726986
Clin Pharmacol Ther. 2017 Jul;102(1):37-44
pubmed: 27997040
Biol Pharm Bull. 2008 Feb;31(2):231-4
pubmed: 18239278
Adv Exp Med Biol. 2021;1305:231-255
pubmed: 33834403
J Clin Psychiatry. 2003 Dec;64(12):1465-75
pubmed: 14728109
J Pharmacol Exp Ther. 2001 Jun;297(3):1044-50
pubmed: 11356927
Pharmacogenet Genomics. 2009 Nov;19(11):907-9
pubmed: 19741567
Biol Psychiatry. 2003 Nov 1;54(9):879-83
pubmed: 14573314
Lancet Psychiatry. 2016 Jun;3(6):585-90
pubmed: 27133546
J Neurochem. 1996 Jun;66(6):2621-4
pubmed: 8632190
Arch Gen Psychiatry. 1992 Oct;49(10):809-16
pubmed: 1417434
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Int J Mol Sci. 2021 Jun 17;22(12):
pubmed: 34204223
Eur J Health Econ. 2007 Mar;8(1):67-76
pubmed: 17165073
Clin Pharmacol Ther. 2015 Aug;98(2):127-34
pubmed: 25974703
J Psychiatr Res. 2016 Feb;73:86-95
pubmed: 26704739
Clin Ther. 2005 Nov;27(11):1685-95
pubmed: 16368442
Clin Pharmacol Ther. 2012 Oct;92(4):414-7
pubmed: 22992668
Arch Gen Psychiatry. 2004 Nov;61(11):1163-9
pubmed: 15520364
Life (Basel). 2021 Jul 09;11(7):
pubmed: 34357045
Neuron. 2008 Jan 24;57(2):203-9
pubmed: 18215618
Am J Psychiatry. 2006 Jan;163(1):28-40
pubmed: 16390886
Br J Pharmacol. 2012 Jan;165(2):289-312
pubmed: 21718296
Mod Probl Pharmacopsychiatry. 1974;7(0):151-69
pubmed: 4412100
Lancet. 1996 Mar 16;347(9003):731-3
pubmed: 8602004
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Int J Neuropsychopharmacol. 2013 Nov;16(10):2259-72
pubmed: 23931269